Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (121-130 of 198) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancerEmanuela Rossi, Alessandro Morabito, Ermelinda De Maio, et al.
Exploration of Targeted Anti-Tumor Therapy|May 16, 2024
Improving the quality of patient care in lung cancer: key factors for successful multidisciplinary team workingAlessandro Morabito, Edoardo Mercadante, Paolo Muto, et al.
JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trialsMassimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
Plos One|October 1, 2015
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung AdenocarcinomaFederica Zito Marino, Federica Zito Marino, Giuseppina Liguori, et al.
The Lancet. Oncology|July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialJean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.
The Lancet. Oncology|May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Michael McCleod, Maen Hussein, et al.
Oncotarget|September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patientsLucia Kim, Mauro Saieg, Massimo Di Maio, et al.
Future Oncology (London, England)|August 22, 2019
Pembrolizumab in lung cancer: current evidence and future perspectivesGiuliano Palumbo, Guido Carillio, Anna Manzo, et al.
Pageof 20

Showing results (121-130 of 198) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancerEmanuela Rossi, Alessandro Morabito, Ermelinda De Maio, et al.
Exploration of Targeted Anti-Tumor Therapy|May 16, 2024
Improving the quality of patient care in lung cancer: key factors for successful multidisciplinary team workingAlessandro Morabito, Edoardo Mercadante, Paolo Muto, et al.
JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trialsMassimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
Plos One|October 1, 2015
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung AdenocarcinomaFederica Zito Marino, Federica Zito Marino, Giuseppina Liguori, et al.
The Lancet. Oncology|July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialJean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.
The Lancet. Oncology|May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Michael McCleod, Maen Hussein, et al.
Oncotarget|September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patientsLucia Kim, Mauro Saieg, Massimo Di Maio, et al.
Future Oncology (London, England)|August 22, 2019
Pembrolizumab in lung cancer: current evidence and future perspectivesGiuliano Palumbo, Guido Carillio, Anna Manzo, et al.
Pageof 20